ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ABVX
AXSM (35) ALKS (78) AMRX (71) KNSA (71) ⌘ Pro Terminal →

Abivax SA (ABVX) — RQD Stock Rating Cockpit

$84.91 -1.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $84.45

Abivax SA (ABVX) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $7.56B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABVX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Abivax SA (NASDAQ: ABVX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $84.91 (-1.94% 1D, market cap $7.56B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ABVX ranks #210 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABVX compare to AXSM and ALKS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVX carries a Roarable D+ (54/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, AXSM (Axsome Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B) and ALKS (Alkermes plc) posts a B+ grade (78/100 RQD, P/E 31.5x, ROIC 14.0%, cap $7.61B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABVX?
▼

For Abivax SA (ABVX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #210 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $84.45 (-0.54%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C
Cash (11)Whales (5)SEC (16)Macro (10)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
$156 Bull$83 Base$65 Bear
📬 FREE ABVX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABVX)Realized 20D OHLCV Swing Band: ±8.3%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY ABVX SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (30% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$87.98+6.3% Next Q
Q2 (-2Q)
59
Grade C$93.49-3.9% Next Q
Q3 (-1Q)
57
Grade C$89.84-5.5% Next Q
Current
54
Grade D+$84.91-0.7% Hist 90D α
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABVX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABVX currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($98.45) and Max Pain ($89.16) forces dealer call-delta covering toward $156.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABVX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABVX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
4130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.74>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE19% OF RANGE
L: $70$84.91H: $149
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: D+RQD 11 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ABVX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (55)

9.9% ROIC with 42.0% gross margin and 2.21% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 3.74 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

17/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like ABVX
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABVX)

  • ✓Walkthrough of ABVX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ABVX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.51%▼ DESCENDING CHANNEL
2026-11-03O $89.06H $89.06L $84.91C $84.91VOL 843.4K
RES: $96.85SUP: $71.16SMA50: $98.45SMA200: $113.7
$153.5$130.8$108.1$85.44$62.77RES $96.85SUP $71.16$84.912026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABVX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABVX Butterfly Map → + Track ABVX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth

vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABVX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABVX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABVX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABVX)

Health Care Rank #210 of 1015 ⚔️ AXSM vs ABVX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABVX vs. AXSM, ALKS, AMRX, KNSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Abivax SA (ABVX) ranks #210 by composite RQD confidence (54/100, grade D+) and #129 by equity capitalization ($7.56B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with ABVX at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABVX ACTIVE
Abivax SA
D+ 54/100 32.8x — 9.9% -1.94% $7.56B Benchmark Subject
AXSM
Axsome Therapeutics Inc.
D- 35/100 — — -21.9% -5.83% $7.57B /axsm-vs-abvx →
ALKS
Alkermes plc
B+ 78/100 31.5x 86.7% 14.0% -0.99% $7.61B /alks-vs-abvx →
AMRX
Amneal Pharmaceuticals Inc.
B- 71/100 103.2x 36.9% 14.1% -4.97% $7.49B /amrx-vs-abvx →
KNSA
Kiniksa Pharmaceuticals International plc (Class A)
B- 71/100 129.9x 88.5% 9.9% -1.56% $7.25B /knsa-vs-abvx →

2. ABVX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Abivax SA (ABVX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $7.56B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. ABVX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Abivax SA (NASDAQ: ABVX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $84.91 (-1.94% 1D, market cap $7.56B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ABVX ranks #210 in composite RQD confidence.

How does ABVX compare to AXSM and ALKS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVX carries a Roarable D+ (54/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, AXSM (Axsome Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B) and ALKS (Alkermes plc) posts a B+ grade (78/100 RQD, P/E 31.5x, ROIC 14.0%, cap $7.61B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABVX?

For Abivax SA (ABVX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #210 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABVX trading relative to its 50-day, 200-day, and 52-week technical levels?

ABVX last traded at $84.91 (-1.94% on volume of 730,357 shares), positioning the stock -13.75% below its 50-day simple moving average ($98.45) and -25.29% below its 200-day simple moving average ($113.66). Across its 52-week range of $69.81 to $148.83, ABVX sits at the 19.1% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.3% ($77.86 to $91.96).

Direct Sub-Reports: ABVX RQD Cockpit ABVX 12M Forecast ABVX Earnings & Move ABVX Dividends & DRIP ABVX Insiders & 13F ABVX Whale Options ABVX Profit Sankey ABVX News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

ABVX — Abivax SA: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Abivax SA (ABVX) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $84.91 (-1.94% 1D, market capitalization $7.56B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (16/20): Incorporates a 1.05x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Abivax SA (ABVX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..8B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 54/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 2.21% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $69.81 – $148.83 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 1.05x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be assessed from the source data.

  • Key Question #1: Can ABVX sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $148.83 52-week high?
  • Key Question #3: How sensitive is ABVX's 30.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?

ABVX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Abivax SA (ABVX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABVX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABVX Bull vs. Bear Conversation Board — What's Your Call at $84.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABVX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ABVX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $104.77 (+21.0%)
📌 Pinned Debate

Forensic balance sheet scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, a strong foundation for the stock.

Forensic balance sheet scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, a strong foundation for the stock.. When you look under the hood at ABVX, Fundamental Cash Engine is 11/20 with 0.0% gross margins and 9.9% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $148.83. My 12M target is $104.77.

CapAlloc_Nerd 🐂 BULL

@MultipleCompression Fair point on 32.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $67.54 (-22.0%)
Spot @ $86.59

Whale 13F flow scores only 4/20 and FCF yield is 2.21% against a P/E TTM of 32.8, leaving weak institutional support and thin cash retu

Careful chasing ABVX at $86.59. Whale 13F flow scores only 4/20 and FCF yield is 2.21% against a P/E TTM of 32.8, leaving weak institutional support and thin cash returns for the valuation.. Gross margin is 0.0%, but operating margin is 13.9%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $67.54 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%